APHRODITE Seeks People With HIV
The body’s immune system triggers inflammation when a threat is detected. Too much inflammation, however, can damage the body or cause painful symptoms and is often a problem for people with HIV who are on antiretroviral therapy.
NIAID’s new APHRODITE clinical research trial seeks to determine if an experimental drug called CC-11050 is safe, well-tolerated, and effective in reducing inflammation in people with HIV. This study is being conducted at the NIH Clinical Center in Bethesda, Maryland. Participation involves about seven visits over the course of about six months. Volunteers will maintain their current regimen, and compensation will be provided.
Read more about the Phase 1 Study of CC-11050 in HIV-infected Adults with Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE) (study ID NCT02652546)http://www.clinicaltrials.gov/